Association of depth of target lesion response to brigatinib with outcomes in patients with ALK inhibitor-naive ALK+ NSCLC in ALTA-1L.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: D. Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, James Chih-Hsin Yang, Ji-Youn Han, Maximilian Hochmair, Ki Hyeong Lee, Angelo Delmonte, Rosario Garcia Campelo, Dong-Wan Kim, Frank Griesinger, Enriqueta Felip, Raffaele Califano, Alexander I. Spira, Michael Thomas, Scott N. Gettinger, Marcello Tiseo, Yuyin Liu, Pingkuan Zhang, Sanjay Popat
Institutions: University of Colorado Cancer Center, Yonsei University, Yonsei University Health System, Yonsei Cancer Hospital, Samsung Medical Center, Sungkyunkwan University, National Taiwan University Hospital, National Cancer Center, Chungbuk National University, Chungbuk National University Hospital, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Complexo Hospitalario Universitario A Coruña, Seoul National University, Seoul National University Hospital, Carl von Ossietzky Universität Oldenburg, Pius Hospital Oldenburg, Vall d'Hebron Hospital Universitari, The Christie Hospital, The Christie NHS Foundation Trust, Virginia Cancer Specialists, University Hospital Heidelberg, German Center for Lung Research, Yale Cancer Center, University of Parma, Royal Marsden Hospital
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4282034792